Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
- Conditions
- CancerLeukemiaLymphoma
- Interventions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 47
- Registration Number
- NCT00109031
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2010-09-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00107354
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
- Conditions
- TeratomaExtragonadal Germ Cell TumorTesticular Germ Cell Tumor
- Interventions
- Biological: bleomycin sulfateDrug: cisplatinDrug: etoposideDrug: ifosfamideDrug: oxaliplatinDrug: paclitaxel
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 263
- Registration Number
- NCT00104676
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇫🇷Centre Henri Becquerel, Rouen, France
🇸🇰National Cancer Institute - Bratislava, Bratislava, Slovakia
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- Conditions
- Angioimmunoblastic T-cell LymphomaChildhood Burkitt LymphomaChildhood Immunoblastic Large Cell LymphomaHepatosplenic T-cell LymphomaIntraocular LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaChildhood Nasal Type Extranodal NK/T-cell LymphomaRecurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00101205
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Use of Topotecan in Patients With Refractory Acute Leukemia
- Conditions
- Non-Hodgkin's LymphomaLeukemia
- Interventions
- First Posted Date
- 2004-12-31
- Last Posted Date
- 2013-09-25
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 10
- Registration Number
- NCT00100477
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomide
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 47
- Registration Number
- NCT00098774
- Locations
- 🇺🇸
Saint Luke's Hospital - South, Overland Park, Kansas, United States
🇺🇸Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States
🇺🇸SUNY Upstate Medical University Hospital, Syracuse, New York, United States
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateBiological: epratuzumabDrug: cytarabineDrug: prednisoneDrug: pegaspargaseDrug: dexrazoxane hydrochlorideDrug: methotrexateDrug: etoposideDrug: cyclophosphamideDrug: leucovorin calciumBiological: filgrastim
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 134
- Registration Number
- NCT00098839
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 168
- Registration Number
- NCT00096135
- Locations
- 🇺🇸
CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
- Conditions
- Carcinoma, Adrenal Cortical
- Interventions
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Collaborative Group for Adrenocortical Carcinoma Treatment
- Target Recruit Count
- 304
- Registration Number
- NCT00094497
- Locations
- 🇺🇸
National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Bleomycin SulfateBiological: FilgrastimDrug: CyclophosphamideDrug: CytarabineDrug: CisplatinDrug: Doxorubicin Hydrochloride (DOX)Drug: FluorouracilDrug: Leucovorin calciumDrug: EtoposideDrug: PentamidineDrug: PrednisoneDrug: IfosfamideDrug: Trimethoprim-SulfamethoxazoleDrug: MethotrexateDrug: Vincristine SulfateDrug: MethylprednisoloneDrug: Zidovudine (AZT)Radiation: Radiation Therapy
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00002524
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.